Scott Gottlieb Quotes


While faulty information from a digital health tool can influence people to make bad decisions, the risks are far lower than those posed by the usual products FDA subjects to pre-market review.


Citations

Gottlieb, Scott. "Apple's Strategy To Avoid The FDA Starts To Emerge." Forbes, 8 Sept. 2016.

Related Quotes

1st Baron Macaulay. This issue is still debated in America. Until the latter part of the 20th century, businesses could sell supposed medicines without any proof of efficacy or safety. The Government or others had to prove that there was something wrong with the product. Then, that shifted, and the burden of proof fell on the developer and seller of medicines as Macaulay favored, but sellers of vitamins and dietary supplements were exempted and operated under the previous American (anti Macaulay) position. Ironically, political opponents of requiring the drug company to prove safety and efficacy claimed that this was a radical new, untested idea that would inhibit development of medicinals. They did not realize that 150 years earlier, this was a standard, accepted point of view in England. Even into the 21st century, America operated with the inconsistent difference between vitamins and supplements, many of which have no beneficial effect whatsoever, and medicines.


There was no Federal regulation of food and drink then. Fast buck whisky purveyors would include all kinds of ingredients and processes, safe and sanitary or not. Many Americans died or became very sick from eating tainted food then. Even bad whisky had killed many. TR chose whisky as his example, because Congress was filled with heavy drinkers and whisky was then the favorite Congressional drink. Roosevelt, with these tactics got the first federal food regulatory laws passed over enourmous opposition, not unlike the fight over Obamacare which would take place a century later.


Scott Gottlieb
Scott Gottlieb
  • Born: June 11, 1972
  • Nationality: American
  • Profession: Public Servant

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.